Substance use in pregnancy
Authors:
- Suzanne WongSWSuzanne Wong
- Alice OrdeanAOAlice Ordean
- Meldon KahanMKMeldon Kahan
- Society Of Obstetricians And Gynecologists Of CanadaSCSociety Of Obstetricians And Gynecologists Of Canada
- 29 June 2011
- journal article
- practice guideline
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 114 (2) , 190-202
Abstract
Objective: To improve awareness and knowledge of problematic substance use in pregnancy and to provide evidence‐based recommendations for the management of this challenging clinical issue for all health care providers.Options: This guideline reviews the use of screening tools, general approach to care, and recommendations for clinical management of problematic substance use in pregnancy.Outcomes: Evidence‐based recommendations for screening and management of problematic substance use during pregnancy and lactation.Evidence: Medline, PubMed, CINAHL, and The Cochrane Library were searched for articles published from 1950 using the following key words: substance‐related disorders, mass screening, pregnancy complications, pregnancy, prenatal care, cocaine, cannabis, methadone, opioid, tobacco, nicotine, solvents, hallucinogens, and amphetamines. Results were initially restricted to systematic reviews and randomized control trials/controlled clinical trials. A subsequent search for observational studies was also conducted because there are few RCTs in this field of study. Articles were restricted to human studies published in English. Additional articles were located by hand searching through article reference lists. Searches were updated on a regular basis and incorporated in the guideline up to December 2009. Grey (unpublished) literature was also identified through searching the websites of health technology assessment and health technology assessment‐related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.Values: The quality of evidence was rated using the criteria described in the Report of the Canadian Task Force on the Preventive Health Care. Recommendations for practice were ranked according to the method described in that report (Table 1).Benefits, harms, and costs: This guideline is intended to increase the knowledge and comfort level of health care providers caring for pregnant women who have substance use disorders. Improved access to health care and assistance with appropriate addiction care leads to reduced health care costs and decreased maternal and neonatal morbidity and mortality.Keywords
This publication has 112 references indexed in Scilit:
- Nicotine Gum for Pregnant SmokersObstetrics & Gynecology, 2008
- Illicit Drug Use and Adverse Birth Outcomes: Is It Drugs or Context?Journal of Urban Health, 2008
- The Opioid Dependent Mother and Newborn Dyad: Nonpharmacologic CareJournal of Addiction Medicine, 2008
- Economic Evaluations of Smoking Cessation and Relapse Prevention Programs for Pregnant Women: A Systematic ReviewValue in Health, 2008
- Nicotine Replacement and Behavioral Therapy for Smoking Cessation in PregnancyAmerican Journal of Preventive Medicine, 2007
- Retaining women in a prenatal care randomized controlled trial in Canada: implications for program planningBMC Public Health, 2007
- Measurement of gestational cocaine exposure: Sensitivity of infants' hair, meconium, and urineThe Journal of Pediatrics, 1992
- Cocaine convulsions in a brast-feeding babyThe Journal of Pediatrics, 1988
- Presence of Δ9-Tetrahydrocannabinol in Human MilkNew England Journal of Medicine, 1982
- Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: Health, developmental, and social implicationsThe Journal of Pediatrics, 1981